...
首页> 外文期刊>Journal of the Royal Naval Medical Service >The treatment of haematemesis and upper gastrointestinal bleeding in United Kingdom Armed Forces and other deployed units
【24h】

The treatment of haematemesis and upper gastrointestinal bleeding in United Kingdom Armed Forces and other deployed units

机译:英国武装部队和其他部署单位的呕血和上消化道出血的治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction Upper Gastro-intestinal (UGI) bleeding is a significant cause of morbidity worldwide. United Kingdom Armed Forces (UKAFs) are not immune to this condition. There is a substantial body of conflicting evidence regarding initial management and risk stratification. Aim To provide the background knowledge and treatment pathways required to assess and manage a patient adequately during the first 24 hours of an episode of UGI bleeding. Assessment Clinical grading of hypovolaemic shock is inaccurate, but is a broad indicator of severity; the Rockall Score must not be used to assess requirement for intervention. Where laboratory assets are available, the Blatchford score is adequate to assess requirements for intervention. Management The principles of hypotensive resuscitation (target systolic blood pressure 90 mmHg for the first hour) hold true for UGI bleeds. In areas where endoscopy is available within four hours, a restrictive pattern of packed Red Blood Cell (pRBC) transfusion may be beneficial. Despite limited evidence of benefit, Proton Pump Inhibitors (PPIs) should be given routinely in UKAFs. Where available, in cases of variceal and non-variceal UGI Haemorrhage without locally available endoscopy, administration of tranexamic acid and somatostatin or octreotide should be considered.
机译:简介上消化道(UGI)出血是世界范围内发病的重要原因。英国武装部队(UKAF)不能幸免于此。关于初始管理和风险分层,有大量相互矛盾的证据。目的提供在UGI出血发作的最初24小时内充分评估和管理患者所需的背景知识和治疗途径。评估血容量不足性休克的临床分级不准确,但可作为严重程度的广泛指标。洛可尔分数不得用于评估干预要求。在有实验室资产的情况下,Blatchford评分足以评估干预要求。处理降压复苏的原则(第一小时目标收缩压为90 mmHg)适用于UGI出血。在可以在四个小时内进行内窥镜检查的地区,限制性的密集红细胞(pRBC)输血可能是有益的。尽管受益的证据有限,但应在UKAF中常规给予质子泵抑制剂(PPI)。如果存在静脉曲张和非静脉曲张的UGI出血而无局部可用的内窥镜检查,应考虑给予氨甲环酸和生长抑素或奥曲肽。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号